Here's a summary of the attached investor presentation: **1. Financial Highlights:** Quest Laboratories reported strong Q1 FY26 YoY growth: Revenue rose 52% to ₹23.18 Cr, and both EBITDA and PAT saw significant jumps.

FY25 revenue topped ₹100 Cr.

However, operating cash flow for FY25 was negative, affected by working capital. **2. Strategic Initiatives & Growth Drivers:** The company is expanding with a USFDA-compliant injectable facility and a new capsule line (expecting ₹10-12 Cr revenue this year). A ₹30-35 Cr capex over three years and R&D allocation support new products like collagen and advanced injectables, aiming for 18-20% EBITDA margins. **3. Business Developments:** Quest initiated export sales in 2025, targeting 30% domestic growth.

New drug registrations in Myanmar and a ₹2.0 Cr Angola order enhance international sales.

Broader global market expansion is underway. **4. Market Position & Competitive Advantage:** Operating in 16 Indian states/2 UTs, Quest holds approvals for over 1300 formulations across a diverse portfolio.

It leverages government partnerships and an agile supply chain for better operating margins. **5. Investor Implications:** Robust Q1 performance and strategic plans indicate positive growth potential.

Investors should monitor execution risks from significant capex and new market entries, plus working capital management.